Custom service

AI-based Peptide Drug Discovery and Structure Analysis Platform

Apply structure prediction and ai screening to peptide discovery programmes

Turnaround: 4–8 weeksTypical scale: 10^2 – 10^9 members by formatChemistry options: structure-prediction guided screening; ML-based activity scoring; in-silico triage before synthesis

The service is built around structure-prediction guided screening. Depending on the molecule we may move to ML-based activity scoring or in-silico triage before synthesis to improve stability, loading or yield, and every batch is released with ranked candidates with modeling rationale.

Because AI-based Peptide Drug Discovery and Structure Analysis Platform projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.

Reducing synthesis burden on large candidate sets

Prioritizing analogs for synthesis

Programmes expecting AI to replace binding assays

Targets with no assayable readout and no purified protein available

Screening programmes close with a data package: primary screen statistics, confirmation data for each hit, counterscreen results and resynthesized material. Library lots ship with composition QC — representation and identity checks by LC-MS or NGS as the format requires.

Service Highlights

  • Structure-prediction guided screening as the default route, with ML-based activity scoring held as a proven fallback
  • In-silico triage before synthesis worked into the design where the application requires it
  • Every reported hit is confirmed by independent resynthesis and re-testing before it reaches you
  • Analytical confirmation of every intermediate before the final release
  • Library integrity (composition, representation) is measured, not assumed, before screening begins
  • Ranked candidates with modeling rationale delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Library design

    Diversity, degeneracy and deconvolution strategy for AI-based Peptide Drug Discovery and Structure Analysis Platform are fixed in a design document.

  2. Library synthesis or construction

    The library is built with structure-prediction guided screening and its composition is QC'd before screening.

  3. Primary screening

    Screening runs with ML-based activity scoring, with controls and statistics defined in advance.

  4. Hit deconvolution

    Hits are identified and ranked; counterscreens remove non-specific and promiscuous binders.

  5. Hit confirmation

    Every hit is resynthesized and re-tested; only reproducible hits advance.

  6. Hit delivery

    Confirmed hits and Ranked candidates with modeling rationale are delivered with the full screening data package.

Specifications & timeline

Turnaround
4–8 weeks
Typical scale
10^2 – 10^9 members by format
Chemistry options
structure-prediction guided screening; ML-based activity scoring; in-silico triage before synthesis
Deliverable
Ranked candidates with modeling rationale
QC package
Library composition QC, screening raw data, hit confirmation package
Shipping
Ambient (plates, beads) or dry ice (display libraries)

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.